Two patients with RECIST v1.1 PRs had HRD-positive cancers (ATM and BRCA1, which were both biallelic alterations), while 1 patient with a PR had HRD-negative cancer, and 3 were unfortunately unable to be assessed for genomic alterations. Here, ATM is linked to cancer.